InvestorsHub Logo
Followers 45
Posts 5703
Boards Moderated 0
Alias Born 10/28/2009

Re: Turbo_Trader72 post# 515

Wednesday, 10/11/2017 3:10:50 PM

Wednesday, October 11, 2017 3:10:50 PM

Post# of 14015
Saw it yesterday and the FDA application is for new products that Hemostyp would be perfect for. Still I sold off 50000 shares in hopes some might see this as a "Fluff" pr? Who knows but read this.

The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body --as evidenced by years of prior product usage and studies--to be approved for Class III internal surgical use. The program's intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner. This application will run simultaneously with the company's prior Class II application for expanded indication. The market for 2017 for internal surgical hemostatic products is estimated to be more than seven billion, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022. (http://industryarc.com/Report/15189/hemostats-market.html)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent UEEC News